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We report he electron transfer propertics of the NADH:ubiquinone oxidoreductase complex of the respiratory chain (Complex I) in mitochondria 
of cells derived from LHON patients with two different mutations in mitochondrial DNA (mtDNA). The mutations occur in the mtDNA 8enes 
coding for the NDI and ND4 subunits of Complex I, The ND1/3460 mutation exhibits 80% reduction in rotenone-sensitive and ubiquinone- 
dependent electron transfer activity, whereas tile proximal NADH dehydrogenase activity of the Complex is unaffected. This is in accordance with 
the proposal that the NDI subunit interacts with rotenone and ubiquinone. In contrast, the ND4/I 1778 mutation had no effect on electron transfer 
activity of the Complex in inner mitochondrlal membrane preparations; also K., for NADH and NADH dehydrogenase activity were unaffected. 
However. in isolated mitochondria with the ND4 mutation, the rate of oxidation of NAD-linked substrates, but not of suecinate, was significantly 
decreased. This suggests that the ND4 subunit might be involved in specific aggregation of NADH-dependent dehydrogenases and Complex I, 
which may result in fast £solid state') electron transfer from the former to the latter. 
LHON: ND1/3460 mutation: ND4/11778 mutation; El~.ctron transfer; NADH:ubiquinone reductase; Complex I
1. INTRODUCTION 
The Leber hereditary optic neuroretinopathy 
(LHON) is a maternally inherited disease resulting in 
acute bilateral blindness due to retinal degeneration. 
Three replacement mutations in 2 mitochondrial genes 
of the NADH:ubiquinone reductase complex of the re- 
spiratory chain have been identified in LHON 
pedigrees. Wallace et al. found a nucleotide change at 
nt11778 in ND4 converting a conserved Arg to His [1]. 
However, genetic heterogeneity was evident, since only 
about half of the LHON families appeared to have this 
mutation [2,3]. This concept was confirmed by Howell 
et al. who identified a mutation at nt4160 of the NDI 
gene resulting in a substitution of Pro for the conserved 
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Leu in a large LHON family [4]. Huoponen et al. 
identified a third LHON mutation, also in NDI, in 3 
independent families: a G to A change at nt3460 con- 
verting Ala to Thr [5]. 
Although the maternal inheritance of LHON 
strongly suggests a pathogenic role of these mutations, 
there is still little known about th~ energy metabolism 
in LHON and its possible role in the pathogenesis of 
this disease. So far, only Parker et al. has reported 
reduced NADH:ubiquinone reductase activity in an 
LHON family with several neurological symptoms, 
which later was shown to have tt, e ND1/4160 mutation 
[4,6]. 
We analysed Complex I electron transfer activity in 
mitochondria and inner mitochondrial membranes 
derived from peripheral lymphocytes of patients with 
the ND1/3460 and ND4/11778 mutations. In the NDI 
mutations we report a clearcut blockade of rotenone- 
sensitive lectron transfer activity of the Complex. In 
the ND4 mutation both electron transfer and K,, for 
NADH were found to be unaffected in the Complex. 
However, in intact mitochondria with the ND4 muta- 
tion we found decreased rates of oxidation of NADH- 
dependent substrates, but not of succinate. The nature 
of the enzymatic defects in the 2 mutants and their 
possible relation to the pathogenesis of LHON are dis- 
cussed. 
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2. MATERIALS AND METHODS 
The ubiquinone analogue, 2,3.dimethoxy-5-methyl-6-n-deeyl-l.4- 
benzoquinone (DB), was synthesized by Dr. Hase (Department of 
Organic Chemistry, University of Helsinki) [7]. 
Cell lines from one normal control individual, two LHON patients 
with the NDI/3460 mutation and one LHON patient with the ND4/ 
11778 mutation were established by Eps~ein.Barr virus (EBV) trans- 
formation of peripheral lymphocytes. 
For detection of NDI and ND4 mutations from the 4 cell lines the 
AhalI- and SfaNI-RFLP analyses were performed as described 
elsewhere [1.5]. Before analyses the cells were lysed and the DNA 
fragments spanning the mutation sites were amplified by PCR accord- 
ing to Gyllensten [8]. 
Mitochondria were isolated from EBV-transformed cell lines. Cells 
were sedimented by centrifugation and the pellet was resuspended at
250 mg wet weight/ml in isolation buffer (0.25 M sucrose, 25 mM 
MOPS/KOH, pH 7.4, I mM EDTA). The cell suspension was treated 
with 0.12% (w/v) digitonin for 20 s. diluted with 3 vols. of isolation 
buffer and centrifuged at 10 000 × g for 2 min. The pellet was re- 
suspended in isolation buffer and centrifuged at 800 × g for 5 rain. The 
resulting supernatant was centrifuged at 10 000 x g for 5 rain. All the 
centrifugations were performed at +4°C and the incubations in an 
ice-bath. An inner mitoehondrial membrane preparation was further 
isolated from the mitochondrial pellet as previously described [9]. 
The NADH :ubiquinone reductas¢ activity was assayed by following 
2,6-dichlorophenolindophenol (DCIP) reduction at 600 nm [10]. The 
rate of reduction increased linearly with increasing DCIP concentra- 
tion. The assays were performed in 25 mM MOPS/KOH. pH 7.4, 1 
mM EDTA, 25/aM DCIP, 2 mM KCN, 62.5/.tM DB, and 5/ag of 
mitochondrial protein in a 0.8 ml vol. The effect of the ubiquinone 
analogue, DB [7], on the NADH:DCIP reductase activity was tested 
with 150/aM NADH, by varying DB concentration from 1.25/aM to 
62.5/aM. Rotenone (7.5/aM) was used to determine the rotenone- 
sensitive fraction of activity. NADH:K.~Fe(CN)6 reductase indicating 
NADH dehydrogenase activity was assayed in 25 mM MOPS/KOH, 
pH 7.4, and 1 mM EDTA by following the reduction of 0.875 mM 
K_aFe(CN)~ at 410 nm by 1.3--400 /aM NADH. Succinate:DCIP 
reductase indicating succinate dehydrogenase activity was assayed as 
previously described [I 1 ]. Rotenone-sensitive ct-ket oglu- 
tarate:K3Fe(CN)6 reductase and antimycin-sensitive suc- 
cinate:K~Fe(CN)c, reduetase were analysed immediately from isolated 
mitochondria derived from control cells and cells with the ND4 muta- 
tion. The assays were performed in 0.25 M mannitol, 10 mM KCI, 10 
mM potassium phosphate, pH 7.2, 0.2 mM EDTA, 1 mM MgCI,, 2 
mM KCN and 0.2 mM ADP. Reduction of potassium ferricyanide 
was followed at 420-500 nm. either in the presence of 25 /*M 
K~Fe(CN)o, 3-15 mM a-ketoglutarate, 0.63 mM L-malate, or with 6 
/aM K~Fe(CN)6, 6.3 mM succinate, and 7.5 gM rotenone. The oxida- 
tion of NAD-linked substrates was corrected for rotenone-insensitive 
activity. Oxidation of succinate was corrected for antimycin-insensi- 
tive activity by addition of 0.3/ag/ml antimycin. All the activities are 
expressed a5 nmol/min.mg mitochondrial protein. Protein concentra- 
tions were assayed with the BCA Protein Assay Reagent (Pierce). 
3. RESULTS 
The control cell line was confirmed not to have either 
NDI or ND4 mutations while the cell lines ND1 and 
ND4 were homoplasmic for nt3460 and nt11778 muta- 
tions, respectively (see Materials and Methods). 
The inner mitochondrial membrane fraction from 
controls and cells with the ND1/3460 and ND4/11778 
mutation all showed a very similar specific succinate 
dehydrogenase activity suggesting that these prepara- 
tions were of similar purity. Thus also other specific 
enzyme activities hould be comparable (Table I). 
Table I 
Complex I activity in inner mitochondrial membranes 







87 100 29 17 
2.6 2.1 ND ND 
44 19 40 39 
1.8 2.4 2.0 2.1 
125 119 63 50 
2.6 2.0 1.7 1.8 
NADH:KjFe( CN)6 
V 2036 2933 2773 2476 
Km 7.1 10.0 8.0 6.7 
SDH 298 258 315 257 
V,,,, (V) and K= for NADH of rotenone-sensitive (R+), rotenone- 
insensitive (R-) and total (T) (NADH:DCIP) reductase, and of 
NADH:K~Fe(CN)6 reductase and succinate dehydrogenase (SDH) 
activity in control, ND4/11778 and two ND1/3460 mutations (NDI/A, 
NDI/B). Vm~ and SDH are expressed as nmol/min.mg, and g,, as/aM 
NADH. ND = not determined. 
All samples exhibited NADH:DCIP reductase activ- 
ity. which in these assay conditions had both rotenone- 
sensitive an5 rotenone-insensitive components (Table 
I). The total NADH:DCIP reductase activities were 
nearly identical in the control and the ND4/11778 muta- 
tion, whereas in the ND1/3460 mutations it was about 
50% of the contol. In the control the rotenone-sensitive 
fraction was 70% of total activity, in the ND4/11778 
mutation 85%, and in the ND1/3460 mutations about 
40%. In the ND1/3460 mutations the rotenone-sensitive 
activity was only about 20-35% of the control, whereas 
the rotenone-insensitive activity was normal. 
The Km for NADH and Vm,,~ were analysed in all 
samples and determined by the Lineweaver:Burk 
method for the total, the rotenone-sensitive and the 
rotenone-insensitive activities (Table I). All K,, values 
ranged from 1.7/.tM to 2.6/.tM, except the rotenone- 
sensitive activity in the ND1 mutations, which was not 
linear enough for the estimation of Kin. This result 
suggests that NADH binding to the enzyme is undis- 
turbed in both LHON mutations. It also suggests that 
both rotenone-sensitive and rotenone-insensitive activ- 
ity in these assay conditions may involve the same 
NADH binding site. 
The proximal NADH dehydrogenase gment of the 
NADH:ubiquinone reductase was analysed by 
NADH:ferricyanide reductase activity. All samples 
showed a similar Vm~x with Km ranging from 6.7-10.0 
/IM (Table I). This strengthens the view that the pro- 
ximal part of the enzyme is unaffected in both LHON 
mutations. 
As shown in Table II, in mitochondrial membranes 
from control cells the rotenone-sensitive NADH:DCIP 
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Table II 
Complex I activity in inner mitochondrial membranes 
Control ND4 NDI/A NDI/B 
R+ DB-  1 7 5 I 
DB+ 83 99 29 14 
R-  DB-  37 18 53 41 
DB+ 33 21 33 38 
T DB-  38 25 58 42 
DB+ 116 120 62 ' 53 
tochondria from ND4 and control cells. Table III shows 
that oxidation of NAD-linked substrates is substan- 
tially depressed in ND4 mitochondria relative to con- 
trols, whilst the succim~te oxidation rates are, in fact, 
somewhat enhanced. The latter difference could well 
relate to a difference in protein composition of the mi- 
tochondria of controls and ND4 mutants. If, therefore, 
the NADH oxidase activities are normalised with 
respect to succinate oxidase activity, it follows that 
NADH-oxidase activity is depressed about 7-fold in the 
ND4 mitochondria relative to the control. 
Total (T), rotenone-sensitive (R+) and rotenone-insensitive (R-)  re- 
duction of DCIP by NADH in the absence (DB-)  and presence (DB+) 
of62.5.uM ubiquinone analogue DB. Activities are expressed as nmol/ 
rain.rag. (For experimental conditions, see Materials and Methods.) 
ND4, ND4/11778 mutation. NDI/A and NDI/B, mutation in NDI/ 
3460. 
reductase activity depended almost completely on addi- 
tion of the ubiquinone analogue DB. In contrast, ro- 
tenone-insensitive activity was unaffected by DB. This 
indicates that the water-soluble redox mediator DCIP 
is unable, on its own, to accept electrons from en- 
dogenous ubiquinone in the membrane, so that a pro- 
ximal, rotenone-insensitive, activity is measured. DB, 
which is more hydrophilic than ubiquinone- 10 (UQ- 10), 
has been shown to readily accept electrons from the 
UQ-10 pool in a rotenone-sensitive fashion [7,12]. Thus, 
in the conditions employed here, DB mediates electron 
transfer between this pool and the water-soluble DCIP. 
Table II also shows that the defect in the NDI 
mutants is specifically related to the failure of DB to 
induce rotenone-sensitive activity. On the other hand, 
the DB-induced enhancement is similar to the control 
in the ND4 mutant. This is in accordance with the data 
of Table I, and indicates that in the ND1 mutant the 
defect is located in the distal rotenone-sensitive ubi- 
quinone-reducing part of Complex I. 
Whereas the ND1 mutation thus exhibits a clearcut 
enzymatic defect in Complex I, the ND4 mutation is 
more problematic as it shows no significant deficiency 
in the inner mitochondrial membrane preparations. We 
therefore studied rotenone-sensitive oxidation of NAD.  
dependent substrates, and of succinate, in intact mi- 
Table III 
Substrate oxidation in mitochcndria 
Control ND4 
:t.Ketoglutarate + L- 44.4 _+ 3.4 (3) 10.2 + 2.6 (3) 
malate 
Succinate 22.1 + 6.4 (4) 36.4 _+ 6.7 (4) 
Reduction of K~Fe(CN)6 by ,v.keloglutarate + L-malate, and by suc- 
cinate, in intact mitochondria from cells of controls and with the 
ND4/I 1778 mutation. Activities are expressed as nmol/min.mg; mean 
± SD, number of assays in parentheses. (For experimental conditions, 
see Materials and Methods.) 
4. DISCUSSION 
In this report we show that electron transfer of the 
NADH:ubiquinone reductase complex (Complex I) was 
dramatically reduced in the ND1/3460 mutation. The 
NDI gene product has been identified to bind rotenone 
and to interact with ubiquinone [13,14]. This is in good 
agreement with our results, since in the ND1/3460 muta- 
tion only rotenone-sensitive electron transfer was 
blocked. Whether this is due to a defect in ubiquinone 
interaction with the complex o," a reduction of electron 
transfer velocity proximal to the ubiquinone interaction 
remains to be clarified. 
The ND4 gene product is suggested to be an Mr 
39 000 membrane-spanning protein of the hydrophobic 
fragment of Complex I [14]. So far, there is nothing 
known about its function, which also applies to most of 
the 30 subunits of the complex. We could not show any 
significant reduction of Complex 1 electron transfer ac- 
tivity in the ND4/11778 mutation, neither were Km for 
NADH nor NADH dehydrogenase activity affected. 
The maternal inheritance of LHON, together with the 
observed mutations in mtDNA-encoded subunits of the 
NADH:ubiquinone reductase complex, suggest hat a 
defect in this enzyme complex is likely to be central in 
the pathogenesis of this disease. In this sense the clear 
defect attributable to the function of the NDI gene 
product in LHON patients with the ND1/3460 mutation 
is interesting. It is also interesting that the LHON 
family with reduced Complex I activity reported by 
Parker et al. [6] has a mutation in the NDI gene though 
at a site different from the ND1/3460 mutation studied 
here [4]. On the other hand, we also show here that in 
an LHON patient with the ND4/11778 mutation con- 
firmed in the lymphoblastoid cell line, the correspond- 
ing enzyme complex has normal electron transfer activ- 
ity. The conservative view that an NADH:ubiquinone 
reductase defect is the pathogenic basis for LHON 
would thus require the hypothesis that the ND4 muta- 
tion results in Complex I being affected in some other 
function than electron transfer between NADH and 
ubiquinone. If this other function were energy conserva- 
tion (proton translocation [15,16]), the overall patho- 
physiological effect may well be analogous to that in the 
ND! mutations, i.e. a decrease in ATP synthesis. How- 
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ever, during the course of this work Larsson et al. [17] 
have reported that the 1VD4/11778 mutation does not 
significantly affect the yield of  ATP synthesis (P/O 
ratio) in isolated mitochondria from muscles of LHON 
patients. This argues against a defect in energy con- 
servation. Larsson et al. [17] also reported unaffected 
electron transfer activity of Complex I itself, but 
lowered activities of oxidation of NADH-linked sub- 
strates in mitochondria, in good agreement with the 
present data. 
It is usually thought (but see [18,19]) that NADH- 
linked dehydrogenases (e.g. those of the Krebs cycle), 
which are located in the mitochondrial matrix, com- 
municate with the NADH-oxidizing Complex I by 
means of diffusion of the dinucleotide. However. many 
of these dehydrogenases have been shown to associate 
to Complex I [18,19], and this may have kinetically 
important implications. The dissociation of NAD(H) 
from the enzymes, and/or its diffusion between binding 
sites of Complex I and dehydrogenases, may be signifi- 
cantly slower than direct 'solid state' transfer or 'sub- 
strate channeling' [19] of reducing equivalents within an 
enzyme-enzyme complex. If this were indeed the case, 
there would have to be specific association domains in 
Complex I for binding of the dehydrogenases. If the 
function of the ND4 subunit were to form such a 
domain, its mutation could lead to depressed activities 
of substrate oxidation without a discernible change in 
the activity of Complex I itself, as observed here (and 
see [17]). 
It is probably essential that Complex I electron trans- 
fer activity is not reduced by more than about 80% in 
the mutations described here; complete inhibition 
would most likely be lethal. Thus, most tissues may 
function virtually normally at Complex I activities well 
below V. ..... and/or by compensating the defect by sec- 
ondary mechanisms. Only a few tissues may be depend- 
ent on the maximal kinetic capacity of Complex I, or 
may lack sufficient compensatory mechanisms for the 
primary defect. This may explain the unique tissue spe- 
cificity of LHON. 
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